US 11254912
Methods and compositions for treating cancer
granted A61KA61K2039/505A61K2039/804
Quick answer
US patent 11254912 (Methods and compositions for treating cancer) held by CRISPR THERAPEUTICS AG expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/804, A61K2039/852, A61K2039/86